Pin OM-M 25 Tablet (Metoprolol Succinate)

May cause sprue-like enteropathy (Symptoms: Severe, chronic diarrhoea w/ substantial wt loss). Dizziness, headache, abdominal pain, dyspepsia, diarrhoea, gastroenteritis, nausea, bronchitis, pharyngitis, rhinitis, arthritis, back pain, skeletal pain, fatigue, flu-like symptoms, angioedema, peripheral oedema, haematuria, UTI, hyperkalaemia, hypertriglyceridemia, hyperuricaemia, hyperglycaemia, elevated liver enzymes. Potentially Fatal: Acute renal failure.

Increased risk of hyperkalaemia w/ ACE inhibitors, K-sparing diuretics, K salts or K supplements and drugs that may increase serum K (e.g. ciclosporin, eplerenone). May potentiate BP lowering effects w/ other antihypertensives. May decrease glomerular filtration w/ NSAIDs which can cause acute renal failure. May increase serum concentrations and toxicity of lithium.

Dosage

Pin OM-M 25 Tablet
Pin OM-M 50 Tablet

Biliary obstruction. Pregnancy.

Olmesartan is a selective and competitive angiotensin II Type 1 (AT1) receptor antagonist that blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II. As a result, olmesartan relaxes blood vessels, hence lowering BP and increases blood supply and oxygen to the heart. Absorption: Bioavailability: Approx 26%. Time to peak plasma concentration: Approx 1-2 hr. Distribution: Volume of distribution: 17 L. Plasma protein binding: ≤99%. Metabolism: Olmesartan medoxomil undergoes ester hydrolysis in the GI tract to active form olmesartan. Excretion: Via faeces (50-65%) and urine (35-50%) both as olmesartan. Terminal half-life: Approx 10-15 hr.

Patients w/ aortic or mitral valve stenosis, renal artery stenosis; at risk for hypotension (e.g. patients w/ volume or salt depletion); history of angioedema; at risk for hyperkalaemia (e.g. patients w/ DM). Severe renal and hepatic impairment. Lactation. Monitoring Parameters Monitor BP, serum creatinine and K levels periodically.